GlassScriptPhysician profile
Salvatore Trazzera
NPI 1568469757
$2,428.17
in general payments reported to CMS, 2019-2025
23 companies · $674 in 2025
The $674 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $108 · 2021: $592 · 2022: $344 · 2023: $151 · 2024: $211 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,035.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $526.24 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $379.91 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $253.29 | 2019-2022 | |
| Boston Scientific Corporation | $228.86 | 2024-2025 | Farapulse, Varithena Administration Pack |
| Bayer Healthcare Pharmaceuticals INC. | $160.29 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $158.64 | 2021-2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.24 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $109.06 | 2019 | |
| Baxter Healthcare | $104.29 | 2022-2025 | Hillrom - Carnation Ambulatory Monitor |
| Acerus Pharmaceuticals Corporation | $40.60 | 2022 | |
| Amarin Pharma, INC. | $38.45 | 2019-2020 | |
| Axsome Therapeutics, INC. | $33.10 | 2025 | Auvelity |
| Philips North America LLC | $30.46 | 2025 | Mcot |
| Daiichi Sankyo INC. | $27.55 | 2024 | Injectafer |
| Medicomp INC | $27.06 | 2025 | Telepatch Cardiac Monitor |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $26.59 | 2019 | |
| Abbott Laboratories | $24.38 | 2025 | Cardiomems |
| Bardy Diagnostics, INC. | $23.96 | 2022 | |
| Lilly USA, LLC | $23.16 | 2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $23.16 | 2022 | |
| Merck Sharp & Dohme LLC | $20.79 | 2023 | Verquvo, Belsomra, Steglatro |
| Exact Sciences Corporation | $19.63 | 2025 | Cologuard Collection Kit |
| Clarus Therapeutics INC. | $15.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salvatore Trazzera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.